The Dose per Fraction May be correlated with Late Kidney Toxicity after Total Body Irradiation: a Single Institution Experience
Advances in Hematology and Oncology Research · 2019
DOI: 10.33140/ahor.02.01.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Hematology and Oncology Research, 2019.
Abstract (Originalsprache)
Background
The purpose of the present study was to retrospectively evaluate the subacute or late toxicities in the kidney, lung, and liver after two total body irradiation regimens, 12 Gy in 6 fractions (group A) and 12 Gy in 4 fractions (group B).
Methods
Forty-two patients who underwent total body irradiation (group A, n=32; group B, n=10) between June 1997 and June 2013 were included in the present study. The median follow up period was 60 months (range: 3–219 months) for the patients in group A and 143 months (range: 5–220 months) for the patients in group B. We evaluated the renal, pulmonary, and hepatic toxicities using the Common Terminology Criteria for Adverse Events version 4.0.
Results
There were 4 cases of chronic kidney disease (group A, n=1; group B, n=3). Although the cumulative incidence of chronic kidney disease differed significantly between the two total body irradiation regimens (p=0.014), the pulmonary and hepatic toxicities did not differ to a statistically significant extent.
Conclusion
The present study suggests that a higher dose per fraction caused a higher incidence of chronic kidney disease.
Zitieren
APA
(2019). The Dose per Fraction May be correlated with Late Kidney Toxicity after Total Body Irradiation: a Single Institution Experience. Advances in Hematology and Oncology Research. https://doi.org/10.33140/ahor.02.01.02
Vancouver
The Dose per Fraction May be correlated with Late Kidney Toxicity after Total Body Irradiation: a Single Institution Experience. Advances in Hematology and Oncology Research. 2019. doi:10.33140/ahor.02.01.02
BibTeX
@article{euvimed2019,
title = {The Dose per Fraction May be correlated with Late Kidney Toxicity after Total Body Irradiation: a Single Institution Experience},
journal = {Advances in Hematology and Oncology Research},
year = {2019},
doi = {10.33140/ahor.02.01.02}
}
EUVIMED